Anglo French Drugs & Industries Ltd is a well-established player in the pharmaceutical sector, known for its quality, innovation, and diverse product portfolio.
With a strong presence in both domestic and international markets, the company has built a reputation for delivering high-quality healthcare solutions.
As of February 23, 2025, the company’s stock is trading at ₹2,750 per share on the Small Exchange, marking its 52-week high.
The 52-week low stands at ₹1,320, showcasing the stock’s volatility.
This article provides an in-depth analysis of Anglo French Drugs & Industries Ltd, covering its financial performance, market trends, technical analysis, shareholding patterns, and expert price targets for 2025, 2030, and 2035.
Company Overview
Anglo French Drugs & Industries Ltd operates in the pharmaceutical industry, focusing on research, development, and manufacturing of high-quality medicines.
The company’s dedication to innovation and patient care has made it a trusted brand in the healthcare sector.
Company Summary
| Details | Information |
|---|---|
| Company Name | Anglo-French Drugs & Industries Ltd |
| Industry | Pharmaceuticals |
| Founded | 1923 |
| Market Cap | ₹500+ Crore (Estimated) |
| Stock Exchange | Small Exchange (Unlisted on NSE/BSE) |
| Demat Status | NSDL/CDSL |
Financial Performance
Anglo French Drugs & Industries Ltd has reported strong financial results, driven by consistent revenue growth and high-profit margins.
Financial Comparison
| Particulars | Previous Year | Current Year | Growth (%) |
|---|---|---|---|
| Revenue (INR Cr) | ₹95 Cr | ₹102.51 Cr | +7.91% |
| Net Profit (INR Cr) | ₹175 Cr | ₹190.94 Cr | +9.07% |
| EPS (₹) | ₹1,350 | ₹1,478 | +9.48% |
| P/E Ratio | 1.72 | 1.86 | +8.14% |
| Debt/Equity Ratio | 0.42 | 0.39 | -7.14% |
The company’s net profit of ₹190.94 crore and EPS of ₹1,478 indicate strong earnings potential, making it an attractive investment opportunity.
Market & Industry Trends
The pharmaceutical sector in India is expected to grow at a CAGR of 10-12%, driven by:
- Rising healthcare demand
- Government initiatives like PLI schemes
- Increasing R&D investments
- Export opportunities in regulated markets
Competitor Comparison
| Competitor | Market Share (%) | Revenue (INR Cr) | P/E Ratio |
|---|---|---|---|
| Sun Pharma | 7.8% | ₹41,542 Cr | 28.5 |
| Dr. |
Reddy’s Labs4.2%₹26,359 Cr22.3Cipla5.1%₹23,895 Cr31.2Anglo French Drugs0.8%₹102.51 Cr1.86
While Anglo-French Drugs has a smaller market share, its growth potential in niche pharmaceutical segments remains strong.
Technical Analysis
Anglo-French Drugs' stock price has shown strong momentum, with key technical indicators signaling bullish trends.
Technical Indicator
| Technical Indicator | Value | Interpretation |
|---|---|---|
| 50-Day Moving Avg | ₹2,580 | Bullish |
| 200-Day Moving Avg | ₹2,250 | Bullish |
| RSI (Relative Strength Index) | 68 | Overbought |
| MACD | Positive | Bullish |
With RSI near 70, the stock is approaching an overbought zone, suggesting a possible short-term correction.
Shareholding Details
Institutional investors hold a significant stake in the company, indicating strong market confidence.
Shareholding Details
| Shareholder Name | % Holding | No. |
|---|
of SharesPromoters60.5%30,25,000FIIs15.2%7,61,000DIIs10.8%5,40,000Retail Investors13.5%6,75,000
Share Price Target for 2025
Analysts predict strong growth for Anglo-French Drugs based on robust financials and expansion strategies.
Broker/Analyst Price Target
| Brokerage/Analyst | Target Price (₹) | Recommendation |
|---|---|---|
| Motilal Oswal | ₹3,200 | BUY |
| ICICI Securities | ₹3,050 | HOLD |
| HDFC Securities | ₹2,900 | HOLD |
Share Price Target for 2030 and 2035
Long-term investors are keen on Anglo French Drugs & Industries Ltd due to its strong fundamentals, growth in the pharmaceutical sector, and increasing global demand for healthcare products.
The company’s expansion strategies, R&D investments, and new product launches will play a crucial role in determining its long-term share price growth.
Long-Term Price Target
| Timeframe | Low Target (₹) | High Target (₹) | Expected Growth (%) |
|---|---|---|---|
| 2030 | ₹5,500 | ₹6,800 | +120% to +150% |
| 2035 | ₹8,500 | ₹10,500 | +210% to +280% |
Based on industry growth trends and the company's financial trajectory, Anglo-French Drugs' stock could see a CAGR of around 15-18% over the next decade.
Risks & Challenges
While the company has strong growth potential, investors must consider risks such as:
- Regulatory hurdles in the pharmaceutical sector
- Competition from larger pharma companies
- R&D risks if drug development fails
- Market volatility and economic downturns
Risk Impact
| Risk Factor | Impact on Stock | Likelihood |
|---|---|---|
| Regulatory Changes | High | Medium |
| Competitive Pressure | Medium | High |
| R&D Failures | High | Medium |
| Market Volatility | Medium | High |
Mitigation Strategy: Investors should monitor regulatory developments, assess competition, and diversify investments to reduce risk exposure.
Conclusion – Should You Invest in Anglo-French Drugs & Industries Ltd?
Based on the fundamental analysis, technical indicators, and market trends, Anglo French Drugs & Industries Ltd presents a strong long-term investment opportunity in the pharmaceutical sector.
- Short-Term View (2025): Moderate growth potential, with a price target of ₹3,000-₹3,200.
- Mid-Term View (2030): Strong growth expected, with the stock potentially reaching ₹5,500-₹6,800.
- Long-Term View (2035): High growth potential, targeting ₹8,500-₹10,500.
Final Recommendation:
✅ BUY for long-term investors
⏳ HOLD for medium-term investors
⚠️ Short-term investors should watch for volatility and corrections
FAQs – Anglo French Drugs & Industries Ltd Share Price Target
Is Anglo French Drugs & Industries Ltd a good investment for 2025?
Yes, the company has strong financials, a low P/E ratio, and good growth prospects.
However, investors should be aware of market risks.
What is the expected CAGR for Anglo-French Drugs over the next decade?
The stock is expected to grow at a CAGR of 15-18% based on market trends and expansion plans.
Will Anglo-French Drugs stock reach ₹10,000 by 2035?
If the company sustains growth, expands globally, and launches innovative products, a price range of ₹8,500-₹10,500 is possible by 2035.
What are the major risks for Anglo-French drug investors?
Regulatory changes, competition from big pharma, and R&D failures are the biggest risks.
Are Anglo-French Drugs listed on NSE or BSE?
No, the stock is currently traded on the Small Exchange and is not listed on NSE or BSE.
Thanks for reading! Anglo French Drugs & Industries Ltd Share Price Target – 2025, 2030, 2035 you can check out on google.